INTRODUCTION
Interferon (IFN) is an essential component of therapy for patients with chronic hepatitis C virus (HCV) infection. In general, the efficacy of IFN is mainly determined by the HCV genotype and quantity of serum HCV-RNA before treatment!-•); however, the host immune response may play an important role in the elimination of HCV during IFN treatment 5 -7 ) . The host cellular immune defense, including the CD4+ and CDS+ T-cell responses, is activated in patients with HCV infection. HCV -specific cytotoxic T lymphocyte (CTL) response is thought to cause hepatic injury and determine the course of an HCV infections-Jo). Peripheral blood mononuclear cells (PBMC) obtained from patients with chronic hepatitis C showed CTL responses to core, El, E2, NS3, NS4, and NS5 epitopes presented as synthetic peptides on human leukocyte antigen (HLA) class I -matched target cells 11 i . The presence of intrahepatic HCV -specific CTLs in patients with chronic hepatitis C has also been reported 8 • 9 • 12 ' 13 ) . The CTL response appears to be relatively weak and has an inverse relationship with the HCV virus titer, suggesting that the induction of CTL response might be a useful therapeutic antiviral strategy 14 i.
Although the specificity of HCV CTL epitopes has been studied in detail, there has been little study of CTL activity during IFN treatment in patients with chronic hepatitis C. IFN has been shown to up-regulate the expression of HLA class I antigen on liver cells 15 i, suggesting that it enhances HCV viral antigen presentation. Since several HLA-A2 -restricted HCV CTL epitopes have already been reported 1 1), the present study was designed to determine HLA-A2-restricted cytotoxic T cell activity during interferon beta (IFN -jJ) therapy in patients with chronic hepatitis C and whether there is any relationship between CTL response and clinical response to IFN-jJ therapy.
MATERIALS AND METHODS

Patients
Eight patients with chronic hepatitis C and HLA-A2 molecules, two HCVnegative healthy subjects with HLA-A2 molecules, and two chronic hepatitis C patients without HLA-A2 molecules participated in this study after giving written informed consent. The characteristics of the 8 patients with chronic hepatitis Care 16 l . Patients were treated initially with 6 million U/ ml of IFN-jJ (Toray Co., Ltd., Tokyo, Japan) every day for 8 weeks and then 3 times weekly for the subsequent 16 weeks. Complete response (responders) was defined as undetect able serum HCV-RNA by RT-PCR at 6 months after the IFN treatment ( Table 1) .
Stimulation of PBMC with synthetic peptides
Heparinized blood samples were collected before the start, 4 weeks after the start, and after the end of IFN treatment, and PBMC were obtained by FicollHypaque density gradient centrifugation and were cryopreserved in a CELL BANKER (DIA-IATRON Co., Ltd., Tokyo, Japan). Two peptides (pep-1, YLL-PRRGPRL [35-44] ; pep-2, DLMGYIPLV [132-140]) corresponding to core sequences that were previously reported to have an HLA-A2 restricted CTUll were used for in vitro stimulation of PBMC according to the modified method described by Kita et al. 12 l . Cryopreserved PBMC (rapidly thawed at 3TC and washed three times in cold Hank's balanced salt solution (HESS : GIBCO BRL, Grand Island, NY) were suspended at a cell density of 4 x 10 6 cells/ ml/well in 10 % human AB serum-AIMV (LIFE TECHNOLOGIES, Rockville, MD), and a synthetic peptide (10 ,ug/ml), PPD (5 ,ug/ ml) and IL-2 (20 U / ml) were added on day 0. The cells were incubated at 3TC in a humidified 5% C02 atmosphere. On day 5, the culture was stimulated with PPD (5 ,ug/ml) and IL-2 (20 U /ml). On day 8, the cultures were restimulated with mitomycin C-treated (50 ,ug/ ml) autologous PBMC (1 x 10 6 cells/ ml), a synthetic peptide (10 ,ug/ ml), and IL-2 (20 U /ml).
Cytotoxicity assays
Allogenic HLA-matched EBV -transformed B lymphoblastoid cell lines (B-LCL) were established as target cells from normal donors according t o the method described by Cerny et al.''). The cells were incubated overnight with synthetic peptides at 10 ,ug/ml. Target cells were labeled with 100 ,uCi of 5 'Cr (Amersham Co., Arlington Heights, IL) for 1 hour and washed three times with HBSS. Cytologic activity was determined in a standard 4-h 5 'Cr-release assay using Ubottom 96-well plates containing 10,000 cells/well. All assays were performed in triplicate. Percent cytotoxicity was determined from the formula 100 X [ (experimental release-spontaneous release) I (maximum release-spontaneous release)] at an effector-to-target cell ratio of 20: 1. Maximum release was determined by lysis of target cells with 10% Triton X -100 (Sigma Chemical Co., St. Louis, MO) . HCVspecific CTL responses were considered as positive by the st at istical analysis t o compare the difference between the percent cytotoxicity of pep-1 or pep-2-pulsed target cells and that of nonpulsed target cells.
Statistical analysis
Values for results are presented as means±SD. Welch's t-test was used to compare the difference between the percent cytotoxicity of peptide-pulsed target cells and that of nonpulsed target cells and a CTL response was considered positive when the p value was less than 0.05. Fisher's exact probability test was used to compare the difference between biochemical and virological parameters and the difference between efficacy of IFN in CTL-positive patients and that in CTLnegative patients with chronic hepatitis C at 4 weeks after IFN treatment.
RESULTS
In this study, 5 of the 8 patients with chronic HCV infection were considered to have shown a complete response to IFN-fi treatment (Table 1) . HLA-A2-restricted CTL response was observed in PBMC from 5 of 8 patients at 1 to 3 points in this study (Table 2 ) . There were no significant differences between % cytotoxicities of pep-1-or pep-2-pulsed PBMC and unpulsed PBMC from 2 healthy contr ols with HLA-A2 molecules and 2 chronic hepatitis C patients without HLA-A2 molecules. As shown in Table 2 , HCV -specific CTL responses t o pep-2 were detected in 2 of the 8 patients with chronic HCV infection before treatment with IFN -ft. These two patients (patients 2 and 3) showed HCV -specific CTL responses Representative HCV -specific CTL responses in two patients with chronic hepatitis C are shown in Fig. 1 . Patient 3 was a 63-year-old man who was considered to have shown a complete response to IFN-,8 treatment. His HCV genotype was 2a, and his HCV-RNA level before treatment was low. HCV -specific CTL responses to pep-2 were observed before and at 4 weeks after the start of IFN treatment, and those to pep-1 were observed at the end of IFN treatment (Fig. 1a) . Patient 7 was a 60-year-old woman who was considered to have shown no response to IFN-,8 treatment. Her HCV genotype was 1b, and her HCV-RNA level before treatment was high. HCV -specific CTL response to pep-1 or pep-2 was not observed before IFN treatment, but she showed a newly induced CTL response to pep-2 at 4 weeks after IFN treatment (Fig. 1b) .
A comparison of HCV-specific CTL response-positive (n=4) and -negative (n=4) patients at 4 weeks after the start of IFN-,8 treatment showed that there· were no differences in the AL T levels before and at 4 weeks after the start of IFN treatment, HCV genotype distribution, HCV-RNA levels, and IFN efficacy (Table   3 ).
DISCUSSION
In this study, HLA-A2-restricted HCV-specific CTL responses were observed from PBMC of patients with chronic hepatitis C, and HCV -specific CTL responses were observed at 4 weeks after IFN treatment. However, clinical correlates of HCV -specific CTL response positivity were not observed in this study.
Before IFN therapy, two patients (patient 2 and 3) with chronic hepatitis C showed HCV -specific CTL responses. These two patients showed complete responses to IFN -j3 treatment. Hoffman et al. showed that the presence of HCVspecific CD4+ response in peripheral circulation may be associated with a favorable response to IFN therapy 18 ' , and Nelson et al. showed that the detect able intrahepatic HCV -specific CTL activity before IFN treatment developed a complete response to IFN 13 ' . These studies suggest that the host immune response may be impor tant in determining the outcome of IFN therapy for chronic hepatit is C. Our two patients with HCV -specific CT L response before IFN treatment also developed a CR to IFN. However, it is difficult to judge whether the presence of HCV -specific CTL response before IFN treatment was involved in the eradication of HCV in our two patients showed that a high HCV -specific CTL response to nucleoprotein residues 88-96 was associated with a low titer of serum HCV-RNA in HLA B44-positive patients infected with HCV 141 . In this study, 3 of 5 CR patients with a low titer of serum HCV-RNA (<100 KIU/ml) as well as 3 NR patients with a high titer of serum HCV -RNA (> 100 KIU/ml) had no detectable HLA-A2-restricted HCV -specific CTL response before IFN treatment. Therefore, CTLs recognizing pep-1 and pep-2, which were HLA-A2 -restricted HCV CTL epitopes used in this study, might not play a major role in suppression of the outgrowth of HCV. IFN has been shown to up-regulate the expression of HLA class I antigen on liver cells 151 , and it is therefore possible that IFN may directly augment CTL activity or enhance viral antigen processing and presentation. Indeed, IFN treatment led to an elevated production of various cytokines such as IL-4, IL-6, IL-10, tumour necrosis factor-alpha (TNF -alpha) and transforming growth factor-beta (TGFbeta) 19 ' 201 . These cytokines are involved in the induction of CTL activity. In this study, 3 patients observed HLA-A2-restricted HCV-specific CTL responses at 4 weeks after IFN-jJ treatment. Although only one of the 3 patients showed a complete response to IFN, the other one patient was negative for serum HCV -RNA at 4 weeks after the start of IFN treatment. In this study, no difference was found between clinical parameters in HCV -specific CTL response-positive ( n = 4) andnegative (n=4) patients at 4 weeks after the start of IFN-jJ treatment. This is the first study to show serial HCV -specific CTL activity during IFN treatment. But our data base is small, further study is needed to clarify the relationship between HCV -specific CTL activity and IFN efficacy.
The results of this study are not necessarily evaluating all of the HCV -specific CTL activity. There are various HCV -specific binding motifs even if it limits only HLA-A2 molecules 111 . It is possible that there were only a few patients who were positive for HCV -specific CTL activity in this study because only two peptides corresponding to HCV core sequences were used. In addition, there is a possibility that cryopreserved PBMC influenced the results of CTL activity. Racial differences should also be considered in the selection of peptides. It would also be of value to examine serial change in HCV -specific CTL activity of intrahepatic lymphocytes during IFN treatment. IFN possesses both antiviral and immunomodulatory activities. Elucidation of the mechanisms underlying host immune response against HCV during IFN treatment would contribute to the establishment of better therapeutic approaches.
